- Home
- RCS vs GOSS Comparison
RCS vs GOSS Comparison
Compare RCS & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCS
- GOSS
- Stock Information
- Founded
- RCS 1994
- GOSS 2015
- Country
- RCS United States
- GOSS United States
- Employees
- RCS N/A
- GOSS N/A
- Industry
- RCS Investment Managers
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- RCS Finance
- GOSS Health Care
- Exchange
- RCS Nasdaq
- GOSS Nasdaq
- Market Cap
- RCS 296.3M
- GOSS 347.8M
- IPO Year
- RCS N/A
- GOSS 2019
- Fundamental
- Price
- RCS $7.03
- GOSS $1.84
- Analyst Decision
- RCS
- GOSS Strong Buy
- Analyst Count
- RCS 0
- GOSS 4
- Target Price
- RCS N/A
- GOSS $8.25
- AVG Volume (30 Days)
- RCS 141.1K
- GOSS 3.6M
- Earning Date
- RCS 01-01-0001
- GOSS 08-11-2025
- Dividend Yield
- RCS 10.12%
- GOSS N/A
- EPS Growth
- RCS N/A
- GOSS N/A
- EPS
- RCS N/A
- GOSS N/A
- Revenue
- RCS N/A
- GOSS $124,590,000.00
- Revenue This Year
- RCS N/A
- GOSS N/A
- Revenue Next Year
- RCS N/A
- GOSS $65.50
- P/E Ratio
- RCS N/A
- GOSS N/A
- Revenue Growth
- RCS N/A
- GOSS N/A
- 52 Week Low
- RCS $4.51
- GOSS $0.66
- 52 Week High
- RCS $6.31
- GOSS $1.94
- Technical
- Relative Strength Index (RSI)
- RCS 60.83
- GOSS 70.54
- Support Level
- RCS $7.00
- GOSS $1.67
- Resistance Level
- RCS $7.16
- GOSS $1.94
- Average True Range (ATR)
- RCS 0.06
- GOSS 0.14
- MACD
- RCS -0.02
- GOSS 0.04
- Stochastic Oscillator
- RCS 38.10
- GOSS 86.81
About RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.